

Applicants: Thomas M. Jessell et al.
Serial No.: 10/002,278
Filed : November 2, 2001
Page 3

B2
Cmt

protein. Amino acid sequences of Dorsalin-1 (amino acids 284-427 of SEQ ID NO: 2), BMP-2 (SEQ ID NO: 3), DPP (SEQ ID NO: 4), BMP-6 (SEQ ID NO: 5), VG-1 (SEQ ID NO: 6), Activin-A (SEQ ID NO: 7), TGF-Beta-1 (SEQ ID NO: 8).--

On page 18, lines 4-5, please delete the paragraph which begins "Figure 10 . . ." and insert the following paragraph:

B3

Figure 10 Amino acid comparison of chick dorsalin-1 (B29) (SEQ ID NO: 2) and mouse (B29m) (SEQ ID NO: 9).--

Remarks

The January 22, 2002 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures states that the application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 C.F.R. §1.821(e)-(g) - §1.825(b) or §1.825(d). The Notice also states that a copy of the "Sequence Listing" in computer readable form has not been submitted as required by §1.821(e).

The Notice states that applicant must provide: 1) an initial computer readable form (CRF) copy of the "Sequence Listing"; and 2) a statement that the content of the computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 C.F.R. §1.821(e) or §1.821(f) or §1.821(g) or §1.825(b) or §1.825(d).

In response, applicants without conceding the correctness of the

Applicants: Thomas³ M. Jessell et al.
Serial No.: 10/002,278
Filed : November 2, 2001
Page 4

Examiner's position but to expedite prosecution of the subject application, enclose a computer diskette containing a substitute sequence listing in computer readable form. Applicants attach hereto, as **Exhibit B**, a paper copy of the computer readable form of the substitute sequence listing. Applicants attach hereto as **Exhibit C** a Statement in Compliance with 37 C.F.R. §1.821(f) certifying that the substitute computer readable form contains the same information as the paper copy of the substitute sequence listing attached as **Exhibit B**. Applicants contend that the substitute sequence listing does not contain any new matter. Applicants submit this substitute sequence listing simply to reflect the upgrade in the PatentIn program from applicants' original submission in PatentIn Version 1.0, i.e. the substitute sequence listing submitted herewith is recorded in the current PatentIn Version 3.1.

In addition, applicants have hereinabove amended the specification to include reference to the sequence identifier information (i.e., "SEQ ID NO:") as required by 37 C.F.R. §1.821(d). This amendment does not involve any issue of new matter. Therefore, entry of this amendment is respectfully requested.

Summary

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Thomas M. Jessell et al.
Serial No.: 10/002,278
Filed : November 2, 2001
Page 5


No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, BOX SEQUENCE, P.O. Box 2327, Arlington, VA 22202



John P. White
Reg. No. 28,678

3/22/02

Date